CLINICAL_TRIALS
trial_result
· 2022-04-07
Clinical Trial Update: Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis [Phase 2]
Summary
Phase 2 clinical trial update for two doses of ABX464 in moderate to severe rheumatoid arthritis has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Abivax S.A. | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2022-04-07